Folfox Protocol

DRUG14 trials

Sponsors

Sun Yat-sen University, UNICANCER, Canadian Cancer Trials Group, Sixth Affiliated Hospital, Sun Yat-sen University, Fudan University

Conditions

Advanced CancerAntimetabolitesAntineoplastic AgentsCarcinomaCarcinoma, HepatocellularChemotherapy EffectColon Cancer (High-risk Stage III: pT4N1 or pT1 to 4 N2)Colorectal Cancer

Phase 2

Phase II Trial of Sorafenib Combined With Concurrent HAIC for Hepatocellular Carcinoma

CompletedNCT02981498

Sun Yat-sen UniversityHepatocellular Carcinoma

Start: 2015-06-30End: 2017-04-30Target: 35Updated: 2019-03-06

HAIC Versus TACE for Large and Unresectable Hepatocellular Carcinoma Staged BCLC A/B

CompletedNCT03048123

Sun Yat-sen UniversityHepatocellular Carcinoma

Start: 2015-10-01End: 2017-01-24Updated: 2017-02-09

NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer

CompletedNCT03259035

Canadian Cancer Trials GroupRectal Cancer

Start: 2018-06-29End: 2024-04-25Updated: 2024-10-10

HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC

WithdrawnNCT03803254

Sun Yat-sen UniversityHepatocellular Carcinoma

Start: 2019-01-03End: 2021-01-01Updated: 2019-05-06

HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCC

Sun Yat-sen UniversityHepatocellular Carcinoma

Start: 2018-11-05End: 2019-12-01Target: 100Updated: 2019-01-23

Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityAntimetabolites, Antineoplastic Agents, Carcinoma +6

Start: 2023-07-01End: 2024-08-31Target: 30Updated: 2023-06-22

SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies

TerminatedNCT05039944

Sichuan Baili Pharmaceutical Co., Ltd.Colorectal Cancer

Start: 2021-11-30End: 2022-06-06Updated: 2024-07-18

Phase 3

Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC

CompletedNCT02774187

Sun Yat-sen UniversityHepatocellular Carcinoma

Start: 2016-05-31End: 2018-08-31Updated: 2019-12-05

IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting

CompletedNCT02967289

UNICANCERColon Cancer (High-risk Stage III: pT4N1 or pT1 to 4 N2)

Start: 2017-03-27End: 2025-07-15Updated: 2025-11-17

HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B.

CompletedNCT02973685

Sun Yat-sen UniversityHepatoCellular Carcinoma

Start: 2016-10-01End: 2020-11-28Updated: 2023-06-12

Triplet Combination or Doublet Regimen Versus Chemoradiation as Neoadjuvant Therapy for Locally Advanced Rectal Cancer

Not yet recruitingNCT03975049

Sixth Affiliated Hospital, Sun Yat-sen UniversityChemotherapy Effect, Rectal Cancer

Start: 2019-08-31End: 2029-07-31Target: 933Updated: 2019-06-05

Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal Cancer

RecruitingNCT04516681

Fudan UniversityColorectal Cancer, GLUT3, Vitamin C

Start: 2024-12-01End: 2025-12-01Target: 400Updated: 2024-10-24

Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas

RecruitingNCT06346197

Centre Leon BerardAdvanced Cancer, Gastric Cancer, Metastatic Cancer +1

Start: 2025-12-08End: 2028-05-15Target: 132Updated: 2026-03-25

Unknown Phase

the Effect of ABCC2 Genetic Polymorphism on Neurotoxicity in Gastrointestinal Cancer Patients Receiving Oxaliplatin

Ain Shams UniversityGastrointestinal Cancer

Start: 2021-08-15End: 2022-12-31Target: 120Updated: 2022-08-09

Related Papers

Supplementary Figure S1 from HBV Reactivation in Patients with Hepatocellular Carcinoma Treated with PD-1/-L1 Antibodies and Concurrent Antiviral Prophylaxis Agents: A Prospective Observational Study

2026-02-17

Hepatitis B virus reactivation in hepatocellular carcinoma patients undergoing immune checkpoint inhibitor and concurrent antiviral prophylaxis agents: A prospective observational study.

Journal of Clinical Oncology2025-05-281 citations

Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib plus transarterial chemoembolization in advanced hepatocellular carcinoma: An update on SHATA-001 study.

Journal of Clinical Oncology2025-05-28

A Contrast‐Enhanced Ultrasound Cine‐Based Deep Learning Model for Predicting the Response of Advanced Hepatocellular Carcinoma to Hepatic Arterial Infusion Chemotherapy Combined With Systemic Therapies

Cancer Science2025-04-29

Tumour-free ctDNA detection as a decision tool to support organ preservation in node-negative rectal cancer undergoing neoadjuvant chemotherapy, excision, and observation in the phase II NEO trial (CCTG CO.28).

Journal of Clinical Oncology2025-01-27

Phase II study of organ preservation (OP) in node-negative (NN) low rectal cancer (RC): Updated clinical and patient reported outcomes (PROs).

Journal of Clinical Oncology2025-01-27

Sorafenib plus hepatic arterial infusion of oxaliplatin and fluorouracil vs sorafenib plus transarterial chemoembolization for advanced hepatocellular carcinoma: A biomolecular exploratory, randomized, phase III trial (SHATA-001).

Journal of Clinical Oncology2024-06-011 citations

Postoperative adjuvant hepatic arterial infusion chemotherapy combined with donafenib in hepatocellular carcinoma with solitary large tumor and microvascular invasion: A multicenter, prospective, single-arm, phase II trial.

Journal of Clinical Oncology2024-06-01

Feasibility of circulating tumor DNA (ctDNA) to guide organ preservation in patients with node-negative rectal cancer undergoing neoadjuvant chemotherapy, excision, and observation in the phase II CCTG CO.28 trial.

Journal of Clinical Oncology2023-01-242 citations

CCTG CO.28 primary endpoint analysis: Neoadjuvant chemotherapy, excision and observation for early rectal cancer, the NEO trial.

Journal of Clinical Oncology2021-05-204 citations

Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion

JAMA Oncology2019-05-09519 citations

CO.28: <i>N</i>eoadjuvant Chemotherapy, <i>E</i>xcision and <i>O</i>bservation (<i>NEO</i>) for early rectal cancer.

Journal of Clinical Oncology2019-01-29

Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4 and/or N2) Colon Cancer-A UNICANCER GI-PRODIGE Trial.

2018-10-1915 citations

PRODIGE 52-UCGI 29-CCTG/CO.27 (IROCAS): A multicenter, international, randomized phase III trial comparing adjuvant modified (m)FOLFIRINOX to mFOLFOX6 in patients with high-risk stage III (pT4 and/or N2) colon cancer (a UNICANCER GI-PRODIGE trial).

Journal of Clinical Oncology2018-05-20

Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis.

2018-01-1141 citations